Work

NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2014

Authors: Kurt A. Jaeckle, David Schiff, S. Keith Anderson, Evanthia Galanis, Philip J. Stella, Patrick J. Flynn, Jann Nagina Sarkaria, Caterina Giannini, Bradley J. Erickson, Jan C Buckner

Institutions: Mayo Clinic in Florida, University of Virginia Medical Center, Mayo Clinic, Trinity Health Michigan, Metro-Minnesota Community Oncology Research Consortium

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2259871202

Cites:

Cited by: 4

Related to: 10